Combined Benefits of a PAR2 Inhibitor and Stratum Corneum Acidification for Murine Atopic Dermatitis

J Invest Dermatol. 2016 Feb;136(2):538-541. doi: 10.1016/j.jid.2015.11.011. Epub 2015 Nov 20.

Authors

Takashi Sakai¹, Yutaka Hatano², Haruna Matsuda-Hirose¹, Wei Zhang¹, Daisuke Takahashi³, Se Kyoo Jeong⁴, Peter M Elias⁵, Sakuhei Fujiwara¹

Affiliations

¹ Department of Dermatology, Faculty of Medicine, Oita University, Oita, Japan.
² Department of Dermatology, Faculty of Medicine, Oita University, Oita, Japan. Electronic address: hatano@oita-u.ac.jp.
³ Faculty of Medicine, Oita University, Oita, Japan.
⁴ Division of Applied Research, NeoPharm Co., Ltd., Daejeon, South Korea.
⁵ Dermatology Service, Veterans Affairs Medical Center, San Francisco, California, USA; Department of Dermatology, University of California, San Francisco, California, USA.

PMID: 26967486
DOI: 10.1016/j.jid.2015.11.011

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Animals
Dermatitis, Atopic / chemically induced
Dermatitis, Atopic / drug therapy*
Dermatitis, Atopic / pathology*
Disaccharides / pharmacology*
Disease Models, Animal
Drug Therapy, Combination
Epidermis / drug effects
Immunoglobulins / metabolism
Mice
Mice, Inbred Strains
Oxazolone / pharmacology
Random Allocation
Receptor, PAR-2 / administration & dosage
Receptor, PAR-2 / antagonists & inhibitors*
Receptors, Cytokine / metabolism
Treatment Outcome

Substances

Disaccharides
Immunoglobulins
Receptor, PAR-2
Receptors, Cytokine
Tslpr protein, mouse
Oxazolone
lactobionic acid